Levi & Korsinsky notifies investors that it has commenced an investigation into Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) concerning potential violations of the federal securities laws.
On December 18, 2023, Checkpoint issued a press release announcing that the U.S. Food and Drug Administration had issued a complete response letter for the cosibelimab biologic license application for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. According to Checkpoint's release, "[t]he CRL only cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party contract manufacturing organization as approvability issues to address in a resubmission." Checkpoint's President and Chief Executive Officer stated that "we believe we can address the feedback in a resubmission to enable marketing approval in 2024". On this news, Checkpoint's stock price dropped 44.88%, to close at $1.83 per share on December 18, 2023.
If you suffered a loss on your Checkpoint securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





